Trial Profile
A Single-Arm, Phase 2 Study of Ramucirumab in Combination With Weekly Docetaxel in Patients With Stage IV Non-Small Cell Lung Cancer Following Disease Progression After Prior Platinum-Based Chemotherapy
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 10 Mar 2022
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 10 Mar 2022 This trial has been discontinued in Italy according to European Clinical Trials Database record.
- 01 Dec 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 12 Oct 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Jul 2017.